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2Foreward
The most common response I have encountered after telling people that my
master’s thesis examined the question of people’s preferences over the manner of
their death was some variant of “I want to die in bed at the age of ninety-five, shot
by a jealous husband,” or its Norwegian equivalent “I want to die at the age of
niney-five, skiing in the forest.” So, it was not surprising that designing a survey to
elicit this information was quite a challange—one that I would never have
accomplished without the advice and support of several individuals.
My heartfelt thanks go to my primary supervisor, Ivar Sønbø Kristiansen, for his
enthusiastic support at all stages of this project, and to my co-supervisors, Dorte
Gyrd-Hansen and Jan Abel Olsen, for their insightful comments and suggestions,
particularly with regard to survey design. Kjartan Sælensminde’s critique of an early
version of the survey during my internship at the Directorate of Health and Social
Affairs helped me to define the issues more carefully. Michael Robinson of Mount
Holyoke College (USA) provided important statistical advice. Lastly, I must thank
my family and friends in the United States who have been so understanding of my
desire to study and live in Norway.
Support for this project was provided by a grant from the University of Oslo.
Arna Desser
Oslo, May 2008
3Abreviations and Acronyms
ATP III Adult Treatment Panel III
CEA Cost effectiveness analysis
CUA Cost utility analysis
CVD Cardiovascular disease
NCEP National Cholesterol Education Program
NHLBI National Health, Lung, and Blood Institute
NIL Named disease / indivdual perspective / life-style intervention
NIP Named disease / indivdual perspective / pharmaceutical intervention
NSL Named disease / societal perspective / life-style intervention
NSP Named disease / societal perspective / pharmaceutical intervention
QALY Quality adjusted life-year
UIL Unamed disease / indivdual perspective / life-style intervention
UIP Unnamed disease / indivdual perspective / pharmaceutical intervention
USL Unamed disease / societal perspective / life-style intervention
USP Unamed disease / societal perspective / pharmaceutical intervention
4Abstract
Western countries devote significant resources to prevention of chronic illnesses,
particularly cardiovascular disease (CVD). Consequently, life expectancy increases
but deaths from other causes, such as cancer, also rise. Preferences for additional
longevity later in life may be sensitive to expected cause of death, but this factor is
typically ignored in economic evaluations of chronic disease prevention programs.
We use current Norwegian mortality date to estimate life expectancy gains and
changed distributions of cause of death associated with CVD and cancer prevention
programs.  For realistic levels of risk reduction, prevention programs against CVD
and cancer increase longevity by 6 and 4 months, respectively. We survey a random
sample of 2700 Norwegians, ages 40– 67, to examine preferences for prevention
programs against CVD and cancer when individuals are informed about expected
increases in life expectancy and resulting changes in the distribution of cause of
death in the population. The survey is randomized for named vs. unnamed disease
(CVD/cancer vs. Condition X/Y), medical vs. life-style interventions, and individual
vs. societal perspective. A pilot study improved the design of the final survey.
Results show little evidence that a desire for an “easy” death influenced
respondents’ willingness to participate in a CVD prevention program; respondents
accepted the offer of both CVD and cancer prevention at similar rates of 61%.
Participation decisions were influenced by framing: more were willing to accept
intervention if the disease was named and if treatment involved life-style changes
rather than pharmaceutical treatment. Willingness-to-pay for prevention was low,
with only 26% of the full sample agreeing to pay 150 NOK per month for CVD
prevention, and 28% willing to pay for cancer prevention.
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61. Introduction
In the health care sector, decisions about how best to allocate limited resources
increasingly rely on economic analysis—usually cost effectiveness analysis (CEA)
or cost utility analysis (CUA)—to weigh the costs of a treatment or health
intervention against its benefits, measured in, for example, life-years or quality-
adjusted life-years (QALYs) gained. There is a broad literature critiquing this
methodology with excellent summary discussions in Brazier et al. (2007); Drummond
et al. (2005); Dolan and Olsen (2002); and Nord (1999). Issues range from the validity
of underlying utility assumptions (mutual utility independence between quantity
and quality of life, constant proportional time trade-off, risk neutrality with respect
to life years, and additive separability) to equity issues implied by the assumption
that a “life-year is a life-year” or “a QALY is a QALY,” to concerns about the role of
process utility (see Brouwer et al, 2005). On the basis of these criticisms, policy
makers routinely consider such concerns as minimizing societal differences in
health, age of patient, potential for improved health, previous treatment received,
responsibility for health condition, etc.
Largely ignored in these discussions is the difficult issue of people’s preferences
over the manner of their death. Anecdotal evidence suggests that people prefer an
“easy” death—one that is sudden and relatively pain free-—to death from a disease
that is prolonged, painful and potentially debilitating. A recent review by Hales et al.
(2008) of research on the definition and conceptualization of the quality of death
and dying supports the idea that most consider a “good” death to be relatively free
of pain and suffering. Although studies about end-of-life decision-making have
begun to challenge the assumption that extending life by whatever means is always
desirable (see SUPPORT study, (1995)), there have been few attempts to measure
preferences with regard to interventions that offer benefits in terms of a lower
mortality rate and increased life expectancy for one condition, but ultimately result
7in an increased risk of death from other, possibly less “desirable” diseases1. To
some extent this may be a problem of insufficient information; perhaps individuals
would accurately value the “less desirable death” if informed of its possibility.
However, it is also possible that this scenario violates time independence
assumptions or represents an example of the role of process utility.  In any of these
cases, it is important to have an understanding of preferences over the manner of
death.
This issue is particularly relevant given the predominance in Western societies of
chronic disease as a cause of mortality. James F. Fries (2005) describes these
diseases and what he calls “the compression of mortality” using a multiple-risk-
factors, universal-susceptibility model in which diseases have onset early in life,
follow a progression which is determined by a variety of risk factors, and ultimately
reach a symptomatic threshold at which point the disease can be diagnosed.
Individuals differ with respect to their rates of progression through the disease so
that those individuals with low risk and slow progression may remain below the
symptomatic threshold and die “disease-free” of other causes while those with high
risk and rapid progression will die of the disease. Treatment can slow the rate of
progression and may result in postponement of the disease, i.e. reaching the
symptomatic threshold at a later time, or prevention of the disease, i.e. slowing
progression so that the threshold is never reached. Interventions to treat a given
disease or to reduce the risk factors associated with it also slow progression relative
to other chronic diseases; an individual treated for cardiovascular disease may
avoid a death by heart attack and prolong life enough to die of cancer or develop
dementia instead.
                                                
1  Studies that address these issues often do so as a side point while investigating other questions. In order to
evaluate the procedural invariance of the TTO method, Anne Spencer (2003) conducted an unconventional TTO
survey in which respondents compare a period of ill health with a longer period with a lower quality of life. Her
results indicate a seeming willingness to trade longevity for quality of life. F. Reed Johnson, et al (1998) used
tradeoff questions related to health-state attributes, longevity and cost as a frame for testing a stated-preference
8Additionally, significant emphasis is placed on programs aimed at reducing
cardiovascular disease. In the United States, the Adult Treatment Panel III (ATP III)
of the National Heart, Lung and Blood Institute’s National Cholesterol Education
Program (NCEP) has issued treatment guidelines for cholesterol management, which
include both therapeutic lifestyle changes and statin therapy (Grundy, et. al. 2004).
In conjunction with “National Cholesterol Education Month,” the NCEP encouraged
all adults to “have their cholesterol measured, know their cholesterol numbers and
their risk for heart disease, and follow a heart-healthy lifestyle to lower their risk and
keep it down,” and provided a packet of web-based materials to help individuals
make necessary lifestyle changes (NHLBI, 2007). In Norway, which has one of the
highest and rapidly growing sales of statins among European countries (Rønning,
2008), twelve governmental ministries are participating in a five-year initiative to
promote healthier diets with the aim of reducing chronic diseases such as CVD,
type-2 diabetes, and individual forms of cancer (Ministry of Health and Care
Services, 2007).
This study investigates preferences among Norwegians, aged 40-67, for
preventative intervention against cardiovascular disease and cancer given the
knowledge that increased life expectancy and reduced numbers of death among
patients treated for a given disease will be balanced by greater numbers of deaths
from other causes, e.g. successful treatment of cardiovascular disease will result in
more deaths from cancer and other causes. We decided for ethical reasons to
pursue this indirect method of determining preferences over manner of death rather
than posing the question directly. Our primary hypothesis is that, when provided
with information about changes in life expectancy and distribution of deaths, fewer
individuals will accept preventative interventions against CVD than against cancer,
a result that would be consistent with a preference for an “easy” death over a
                                                                                                                                                      
survey which was intended to measure willingness to pay for reduced morbidity. They report a clear indication that
quality of life affects the value of the quantity of life.
9“hard” one. We also hypothesize that individuals’ willingness to participate in
prevention programs will be affected by whether: (1) the offered intervention entails
a pharmaceutical regime or lifestyle changes, (2) the description of a disease
includes name, e.g. cardiovascular disease or cancer, and symptoms or only
symptoms, and (3) the respondents are asked to consider the program from an
individual or societal perspective. The scenario used in the study was developed
from a model of life expectancy in Norway in which changes in the numbers of
deaths from different causes can be estimated by varying the effectiveness of the
prevention programs.
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2. Methodology
2.1 Model of distribution of deaths from different causes
To obtain estimates of the distribution of deaths by different causes, we created a
simple model based on detailed Norwegian life expectancy and mortality data from
2002. The mortality data provided cause-specific numbers of deaths by sex and one-
year age groups, classified according to the European short-list. We focused on
three causes of deaths, which, for the most part, could be calculated directly from
the 2002 mortality data2: (1) Coronary heart disease [total of Deaths from Ischemic
heart diseases (I20-I25), Cerebrovascular diseases (I60-I69) and one half of Other
heart disease (I30-I33, I39-I52)3], (2) Malignant cancers [deaths from malignant
neoplasm (C00-C97)], (3) Other deaths [Total deaths less sum of (1) & (2)].
Total mortality risk and mortality risks for each of the three categories listed above
were computed by one-year age groups by dividing number of deaths in an age
group by the population for that age group for 2002. For the age groups “under 5”
and “over 100”, numbers of deaths were available only for the whole group so the
individual one-year mortality rates were assumed to be the average rate for the age
group. Beginning with a population of 100 000, and using the mortality risks from
the 2002 data, annual total deaths and deaths in each of the three categories were
calculated and summed to arrive at the distribution of deaths for the population.
These totals formed the basis for the distribution of deaths by different causes
without preventative interventions. The distribution of deaths with a cardiovascular
prevention program in place was then computed by multiplying the relative risk of
                                                
2 Classifications are in accordance with ICD-10.
3 Including half of the deaths in the category ”Other heart disease” is a way of capturing deaths that are likely
attributable to CVD but appear elsewhere in the death statistics.
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heart disease for each age group by a relative risk-reduction factor, and re-
calculating the model, assuming that relative risk for other causes of death remained
the same. We chose to use a risk-reduction factor of 30% based on empirical
evidence on the effectiveness of treatment of coronary heart disease with statins
(Grundy, et. al. 2004). A similar procedure was followed to obtain the distribution of
deaths when a cancer prevention intervention was substituted for the
cardiovascular intervention. In both cases, intervention was assumed to have
begun at age 50. Results are in Table 1.
Table 1. Estimated distribution of deaths and life expectancy per 100 000
individuals
Baseline
Totals
With CVD
intervention
With Cancer
intervention
Cause of Death
Cardiovascular Disease 34 205 27 072 37 044
Cancer 23 613 25 072 17 384
Other Deaths 42 182 47 856 45 572
Life Expectancy (in years) 78.7 79.2 79.0
2.2 Survey description
Using the results from the mortality model, we developed a survey to examine
preferences for prevention programs for cardiovascular disease and cancer when
information about disease symptoms, average increases in life expectancy, and
changes in the distribution of deaths from different causes is provided. The survey
was randomized for: (1) named vs. unnamed disease, e.g. CVD and cancer vs.
Conditions X and Y—to determine if preferences might be influenced by fears
associated with the name rather than the symptoms of a disease, (2) individual vs.
societal perspective—to determine if preferences differ when participation is offered
to the individual or as a program for the general population, and (3) pharmaceutical
12
vs. life-style interventions—to determine if preferences differ based on the type of
prevention treatment offered. We tested the survey design in a pilot study with 15
respondents. Following suggestions, we added a survey version that excluded the
information on changes in the distribution of causes of death, and revised the
format of questions about willingness-to-pay for prevention. We were also able to
refine possible responses to questions about reasons for various choices.
The final survey was structured as follows: After an initial description of the two
diseases (CVD/Condition X and cancer/Condition Y) and a numeric and graphical
presentation of the current distribution of deaths per 1000 individuals, respondents
were asked to imagine that a life-long prevention program (pharmaceutical or life-
style) existed for one of the diseases4, given a description of the intervention and
resulting average increase in life expectancy, and provided with numerical
information and a bar graph comparing the current distribution of deaths with what
would occur with the prevention program. Respondents were then asked if they
would participate in (individual perspective) or favor government provision of
(societal perspective) the prevention program. A positive response led to a further
question about whether they would be willing to pay 150 NOK5 (approximately $30
at $1=5.12 NOK) per month to participate (or pay 150 NOK per month in extra taxes
for a societal program), while a negative or uncertain response led to a question in
which respondents could check reasons for not choosing to participate. The
procedure was repeated for the second disease. Individuals who were willing to
participate in both prevention programs were then asked which one they would
choose if it were possible only to select one. A follow-up question asked
respondents to check reasons for their choice. All participants were asked whether
                                                
4 The order of presentation was varied so that half of respondents were asked first about CVD prevention and the
others about cancer prevention.
5  150 NOK reflects the average monthly cost of a one-year supply of statins and two annual medical examinations to
monitor cardiovascular health. We applied the same cost to all offered interventions (pharmaceutical, life-style, CVD
and cancer) in order to minimize the complexity of the survey.
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they or an immediate family member had ever been diagnosed with CVD or cancer.
The survey concluded with three questions to gauge numeracy.6
With full randomization, there were eight versions of the survey, which can be
described using the initials N (named), U (unnamed), I (individual perspective), S
(societal perspective), P (pharmaceutical intervention), and L (life-style
intervention): NIP, NIL, NSP, NSL, UIP, UIL, USP, USL.7 We included an additional
version, “Short” (named disease, individual perspective, pharmaceutical
intervention), in which only information about disease symptoms and average
increase in life expectancy was provided, with no mention of the distribution of
deaths, so that we could test whether knowledge of the changed distribution of
deaths affected preferences. A native-speaker translated the surveys into
Norwegian.
The survey was conducted via the internet by TNS Gallup during the period March
27 – April 2, 2008. To achieve a random set of sub-samples representative of the
Norwegian population aged 40 – 67, TNS Gallup used the following procedure:
Based on a requested sample size of 2700 individuals and an expected response rate
of 60%, 4509 respondents from among the TNS Gallup access panel of 35,000 pre-
recruited individuals were invited to participate. Respondents were distributed
randomly across the different survey versions, with net response rates of
approximately 60% for all survey versions.
                                                
6 Numeracy tests are frequently used to confirm individuals’ ability to understand risk information presented in
percentage terms. While we do not use percentages in the survey, we felt that the numeracy questions would be,
nonetheless, a useful gauge of whether individuals possessed the analytical ability needed to answer a rather
demanding survey.
7 The ”named disease, individual perspective, pharmaceutical intervention” (NIP) version of the survey is provided
in Appendix 1. A complete set of surveys is available upon request.
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3. Results
3.1 Descriptive results
In total, 2712 individuals responded to the survey. Descriptive statistics for
gender, age, income, level of education, region of residence, experience with CVD
and cancer, and numeracy are grouped by survey version and presented in Table 2.
Table 2. Descriptive statistics of respondents by survey version
Pharaceuti
al Life-Style
Pharaceuti
al Life-Style
Pharaceuti
al Life-Style
Pharaceuti
al Life-Style Short
Variable NIP NIL NSP NSL UIP UIL USP USL Short Total
Number 279 354 296 302 304 303 289 276 309 2712
Gender: % female 52.3 48.0 50.0 49.3 50.3 49.5 47.1 47.8 53.1 49.7
Age, median in years 52 53 53 52 53 52 53 53 51 52
Age, 10%, 90% 
percentiles. (42, 63) (42, 63) (43, 64) (43, 64) (43, 63) (42, 63) (42, 63) (42, 63) (41, 63) (42, 63)
Marital Status, % 
cohabitating 77.8 79.4 74.7 79.8 79.9 78.9 78.9 75.4 75.7 77.8
Household Income, 
median in 1,000 NOK 600-799 600-799 400-599 600-799 600-799 400-599 600-799 600-799 400-599 600-799
Household income, 
10%, 90% percentiles
200-300, 
800-999
200-300, 
800-999
200-300, 
800-999
200-300, 
800-999
200-300, 
1000-1199
200-300, 
1000-1199
200-300, 
800-999
200-300, 
800-999
200-300, 
800-999
200-300, 
800-999
Education % at
Elementary 11.8 9.9 7.4 9.3 7.2 9.2 8.3 7.2 7.4 8.7
High School 29.4 28.2 38.2 31.5 30.6 28.1 32.9 39.1 32.7 32.2
Trade School 31.9 33.6 26.4 32.1 30.9 31.4 30.8 28.6 33.7 31.1
University (1-4 yrs) 16.8 18.4 12.2 15.2 16.1 18.8 13.5 13.4 13.9 15.4
University (4+ yrs) 10.0 9.9 15.9 11.9 15.1 12.5 14.5 11.6 12.3 12.6
Region
Oslo/Akershus 24.1 21.5 23.3 21.2 22.7 21.1 22.8 22.5 21.7 22.3
Rest Østland 25.5 27.4 28.4 26.2 28.9 30 26.3 29 29.8 27.8
Sør-/Vestland 27.7 30.2 28.7 31.1 30.9 29.7 32.5 30.8 30.7 30.3
Tr.lag/Nord-Norge 22.7 20.9 19.6 21.5 18.4 19.1 18.3 17.8 17.8 19.6
CVD: self or 
immediate family, 
%yes 58.8 56.5 56.8 58.9 54.3 60.1 58.5 55.4 59.9 57.7
Cancer: self or 
immediate family, % 
yes 58.4 52.8 63.5 59.6 57.9 56.4 61.9 60.5 57 58.5
Numerate (3 correct 
answers, %) 70.6 74.6 76.7 75.8 71.7 69.3 73.7 74.3 75.4 73.6
Named Disease Unnamed Disease
Individual Perspective Societal Perspective Individual Perspective Societal Perspective
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Randomization of individuals across the different survey versions appears to have
been successful and relatively representative of the Norwegian population. The
survey sample was 49.7% female compared to 49.2% female in the Norwegian
population for the relevant age group. The age distribution for the sample
population was 36.5% age 40-49, 38.6% age 50-59, and 24.8% age 60-67. The
corresponding distribution for the Norwegian population is 40.3% age 40-49, 36.1%
age 50-59, and 23.6% age 60-67. In the sample population, 28% had at least one year
of college education compared to 27% of the Norwegian population in the relevant
age group. All data analysis was performed using SPSS 16.0 for Mac.
Tables 3 and 4 and Charts 1 and 2 summarize the responses to the questions
about whether individuals would participate in (or support provision of) free
prevention programs against CVD and cancer, respectively. Mean support was
61.9% for the CVD prevention program and 61.7% for cancer prevention although
support varied significantly across the different versions of the survey. For CVD
prevention, support ranged from 46% in the USP version to 78% in the NIL version.
Support for the cancer intervention ranged from 42% in the UIP version to 77% in
the NIL version. 14% of respondents declined participation in the CVD prevention
program while 25% were uncertain. For the offered cancer intervention, 14%
declined and 26% were uncertain. Contrary to our hypothesis, there is no significant
difference in individual responses with respect to CVD vs. cancer interventions.
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Table 3. CVD intervention by survey version
Yes No Uncertain Total
Version % % % n
NIP 55.6 17.6 26.9 279
NIL 78.0 6.5 15.5 354
NSP 59.8 11.1 29.1 296
NSL 72.8 7.6 19.5 302
UIP 46.4 23.7 29.9 304
UIL 68.0 11.2 20.8 303
USP 45.7 24.6 29.8 289
USL 52.5 12.7 34.8 276
Short 64.7 12.3 23.0 309
Total 60.9 13.9 25.1 2712
Table 4. Cancer intervention support by survey version
Yes No Uncertain Total
Version % % % n
NIP 57.0 17.9 25.1 279
NIL 76.6 5.4 18.1 354
NSP 64.2 8.1 27.7 296
NSL 76.5 7.3 16.2 302
UIP 42.4 24.7 32.9 304
UIL 65.7 13.2 21.1 303
USP 48.1 21.8 30.1 289
USL 51.8 14.5 33.7 276
Short 59.9 12.6 27.5 309
Total 60.7 13.7 25.6 2712
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Chart 1. Support for CVD intervention by survey version
Chart 2. Support for cancer intervention by survey version
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Individuals who responded “yes” to questions concerning support for free
CVD and/or cancer prevention programs were further asked whether they would be
willing to pay 150 NOK (approximately $30) per month in either personal payments
or extra taxes to participate in or support the program. The responses are
summarized in Tables 5 and 6 and Charts 3 and 4.
Table 5. Willingness to pay 150 NOK for CVD prevention by survey version, as %
of those accepting treatment
Yes No Uncertain Total
Version % % % n
NIP 42.6 25.2 32.3 155
NIL 42.0 26.8 31.2 276
NSP 49.2 20.3 30.5 177
NSL 36.8 34.5 28.6 220
UIP 41.8 32.6 25.5 141
UIL 36.4 30.6 33.0 206
USP 46.2 25.8 28.0 132
USL 44.1 28.3 27.6 145
Short 45.0 26.0 29.0 200
Total 42.3 27.9 29.8 1652
Table 6. Willingness to pay 150 NOK for cancer prevention by survey version, as
% of those accepting treatment
Yes No Uncertain Total
Version % % % n
NIP 41.5 29.6 28.9 159
NIL 45.4 25.8 28.8 271
NSP 56.3 18.9 24.7 190
NSL 45.5 29.0 25.5 231
UIP 41.1 34.1 24.8 129
UIL 40.7 30.2 29.1 199
USP 46.8 26.6 26.6 139
USL 46.2 27.3 26.6 143
Short 49.7 21.1 29.2 185
Total 46.1 26.7 27.3 1646
19
Chart 3. Willingness to pay 150 NOK for CVD prevention by survey version
Chart 4. Willingness to pay 150 NOK for cancer prevention by survey version
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Among the 1652 individuals who supported the CVD intervention, 42% were willing
to pay 150 NOK per month for the program, 28% declined, and 30% were uncertain.
For cancer prevention, the “yes”, “no” and “uncertain” responses were 46%, 27%,
and 27%, respectively, for the 1646 individuals who were willing to participate in a
free program. Assuming that individuals who declined or were uncertain about
participation in the prevention program would not have been willing to pay for it,
only 26% of the entire survey population expressed a willingness to pay 150 NOK
per month for CVD prevention, with 28% willing to pay that amount for cancer
prevention. There was relatively little variation in willingness-to-pay responses
across survey versions.
Respondents answering either “no” or “uncertain” to the offer of prevention
programs were asked to explain their choice by selecting all relevant options from a
list possible explanations. Results for refusal to participate in CVD and cancer
prevention are provided in Table 7 and Table 8, respectively. Possible explanations
differed somewhat across survey versions. All respondents could indicate that they
thought the program was of no value, that they did not want to increase the number
of deaths for the other disease or from other causes, or that they did not want to
experience (or expose others to) side effects. Other possible responses included: not
wanting to extend life (Individual versions), not wanting to take medication
(Pharmaceutical versions), not wanting to change life-style (Life-style versions), not
wanting to pay more taxes (Societal versions) and not believing taxes should be
spent on the programs (Societal versions). Reasons selected least often were “taxes
shouldn’t be used for this purpose” [CVD: 13%, Cancer: 12%], “don’t want to pay
more taxes” [CVD: 13%, Cancer: 14%] and “the program has no value” [CVD: 19%,
Cancer: 20%]. Average frequencies for other reasons ranged from 26% [CVD: “don’t
want to change life-style”] to 40% [Cancer: “don’t want to extend life”], with most
grouped around 33%.
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Table 7. Reasons for not accepting offered CVD prevention as % of respondents
by survey version
Table 8. Reasons for not accepting offered cancer prevention as % of respondents
by survey version
Although a systematic presentation of all of the explanatory responses is beyond
the scope of this paper, several results can be highlighted. The pattern of responses
was similar for decisions to decline CVD vs. cancer prevention with two exceptions:
“I don’t want to extend life” was mentioned more frequently as a reason for refusing
cancer vs. CVD prevention, and “I don’t want to increase cancer deaths” was
mentioned more often as a reason for refusing CVD intervention than was the
comparable “I don’t want to increase CVD deaths” as a reason for refusing cancer
intervention. There was also variation in the frequency of responses across survey
groups. Most notably, “I don’t want to (expose others to) side effects” and “I don’t
want to extend life” were selected more often on “pharmaceutical” than “life-style”
NIP NIL NSP NSL UIP UIL USP USL Total*
Reasons % % % % % % % % %
Not valuable 12.1 14.1 19.3 29.3 13.5 13.4 29.3 19.1 18.8
Don't want to increase cancer deaths 38.7 26.9 38.7 47.6 23.3 18.6 28.0 35.1 31.5
Don't want to increase other deaths 27.4 25.6 41.2 36.6 31.9 20.6 37.6 44.3 33.9
Don't want (to expose others to) side effects 42.7 21.8 44.5 22.0 37.4 24.7 45.9 29.8 35.4
Don’t want to extend life by 6 months 36.3 29.5 39.9 30.9 35.3
Don't like to take medicine 29.0 37.4 33.8
Don't want to change life style 29.5 23.7 26.3
Don't think taxes should be used for this 11.8 14.6 12.7 13.0 12.9
Don't want higher taxes 11.8 17.1 7.6 18.3 13.1
Total Number of Cases (n) 124 78 119 82 163 97 157 131 951
*Percent selecting option relative to total number presented with option. "Short" version cases excluded.
NIP NIL NSP NSL UIP UIL USP USL Total*
Reasons % % % % % % % % %
Not valuable 12.9 15.4 21.0 30.5 16.0 12.4 26.8 20.6 19.6
Don't want to increase CVD deaths 30.6 24.4 30.3 28.0 28.2 19.6 23.6 32.8 27.7
Don't want to increase other deaths 30.6 26.9 32.8 35.4 30.1 18.6 37.6 44.3 33.0
Don't want (to expose others to) side effects 46.0 26.9 45.4 23.2 39.3 25.8 45.2 32.1 37.5
Don’t want to extend life by 4 months 41.1 34.6 47.9 36.1 39.6
Don't like to take medicine 25.8 34.4 29.8
Don't want to change life style 26.9 30.9 27.3
Don't think taxes should be used for this 8.4 12.2 14.0 11.5 12.4
Don't want higher taxes 13.4 15.9 7.6 18.3 14.1
Total Number of Cases (n) 120 83 106 71 175 104 150 133 942
*Percent selecting option relative to total number presented with option. "Short" version cases excluded.
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versions as reasons to refuse both CVD and cancer prevention. “Don’t want to
increase cancer deaths (deaths from Condition Y)” appeared more frequently as a
reason for declining CVD intervention for “named” vs. “unnamed” survey versions
although this was not the case for “I don’t want to increase CVD deaths (deaths
from Condition X)” and refusal to accept cancer intervention.
The 1471 individuals who were willing to participate in (or support) both the
CVD and cancer prevention programs were asked to choose between the programs.
Results are provided in Table 9.
Table 9. Preference for CVD vs. Cancer intervention by survey version
CVD
prevention
Cancer
prevention
Equally
valuable
Don't Know Total
Version % % % % n
NIP 13.0 17.4 68.1 1.4 138
NIL 16.8 25.0 56.6 1.6 256
NSP 9.8 16.0 71.8 2.5 163
NSL 9.9 25.2 62.9 2.0 202
UIP 20.8 14.2 57.5 7.5 120
UIL 20.3 12.3 61.5 5.9 187
USP 19.6 10.7 66.1 3.6 112
USL 18.3 18.3 54.8 8.7 126
Short 6.0 18.0 76.0 0.0 167
Total 14.6 18.4 63.7 3.3 1471
A large majority, 63.7%, indicated that they thought both programs were equally
valuable. Cancer prevention was chosen by 18.4% and CVD prevention by 14.6%,
while 3.3% were uncertain about which program they would choose. The results
also varied by survey version with cancer prevention preferred when the disease
was named and CVD prevention preferred among respondents who answered the
“unnamed” version. Individuals who expressed a preference for one of the
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prevention programs were asked to check answers to explain their reasoning.
Among the 270 respondents who preferred the cancer prevention program, reasons
selected were: “It is worse to die of cancer than CVD” (44%), “Cancer is a more
serious disease than CVD” (41%), “I have a family history of cancer” (20%), and “I
don’t think I will get CVD” (10%). Responses among the 215 individuals who
preferred CVD prevention were: “There is a larger increase in life expectancy” (51%),
“There are more cases of CVD than cancer” (40%), “I have a family history of CVD”
(26%), “It is worse to die of CVD than cancer” (7%), and “I don’t think I will get
cancer” (6%).
3.2 “Short” survey version
The “short” version of the survey posed identical questions to the “named
disease, individual perspective, pharmaceutical intervention” version but removed
all references to changes in the distribution of causes of death resulting from
prevention programs. Chi-squared tests indicated that there were no significant
differences in patterns of answers between the two versions with regard to
willingness to accept cancer prevention treatment, willingness-to-pay for either CVD
or cancer prevention, or the head-to-head choice between the CVD and cancer
prevention programs. Responses patterns were different with regard to willingness
to accept CVD treatment, with fewer respondents agreeing to participate when
information about changes in the distribution of causes of death was provided, but
the result was not strongly significant (p = .058).
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3.3 Multinomial logistic regressions
We preformed multinomial logistic regressions to gain insight into the
determinants of willingness to accept CVD and cancer intervention, of willingness
to pay for treatment among those who said they would accept the interventions,
and of the choice between CVD and cancer intervention. Cases in which
respondents answered the “short” survey version were not included in the
regressions because they received less information about the effects of intervention
than other respondents. All regressions used “yes” as the reference category. Odds
ratios for “no” responses are presented below. Full regression results, including
odds ratios for “uncertain” responses, are reported in Tables 10, 11, 12 and 13.
Willingness to participate in a CVD prevention program was explained by whether
the disease was “named” or “unnamed”, the type of treatment offered, and whether
the respondent had direct experience with CVD and was numerate. The odds of
refusing CVD prevention were 2.2 (p < .001, CI: 1.7 - 2.8) times greater than the odds
of accepting treatment when the respondent answered a survey with “unnamed”
diseases; 2.7 (p < .001, CI: 2.1 – 3.5) times greater when offered drug treatment rather
than life-style intervention; 1.5 (p = .001, CI: 1.2 – 1.9) times greater if there was no
personal experience with CVD; and 1.4 (p = .024, CI: 1.05 – 1.9) times greater if the
respondent was numerate (defined as answering all three numeracy questions
correctly).
For explaining willingness to participate in the cancer intervention, only the type of
treatment offered and whether the disease was “named” or “unnamed” were
significant. The odds of refusing participation were 2.6 (p < .001, CI: 2.1 – 3.4) times
greater than the odds of accepting when the diseases were “unnamed” in the
survey, and 2.4 (p < .001, CI: 1.9 – 3.1) times higher when a pharmaceutical
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intervention was offered. Numeracy increased the odds of refusing the intervention,
but was not significant at the 95% level (p = .076).
Table 10. Multinomial logistic regression results.
Dependent variable: Willingness to accept CVD prevention treatment
Table 11. Multinomial logistic regression results.
Dependent variable: Willingness to accept cancer prevention treatment
We tested a variety of variables in an attempt to explain willingness-to-pay
for the prevention programs, but only found a significant explanatory relationship
for willingness-to-pay for cancer prevention, for which income, personal experience
Odds-ratio Sig. Lower bound Upper bound
Refused participation
Unnamed disease 2.638 < 0.001 2.052 3.392
Drug intervention 2.377 < 0.001 1.852 3.050
Numerate 1.299 0.076 0.973 1.735
Uncertain
Unnamed disease 1.796 < 0.001 1.482 2.177
Drug intervention 1.708 < 0.001 1.409 2.070
Numerate 0.875 0.217 0.707 1.082
Reference category  for dependent variable is: Accepted participation
95% Confidence Interval: Odds-ratio
Reference categories for independent variables are: named disease, life-
style intervention, innumerate
Odds-ratio Sig. Lower bound Upper bound
Refused participation
Unnamed disease 2.182 < 0.001 1.696 2.807
Drug intervention 2.734 < 0.001 2.119 3.529
No CVD history 1.499 0.001 1.169 1.923
Numerate 1.410 0.024 1.047 1.898
Uncertain
Unnamed disease 1.592 < 0.001 1.307 1.938
Drug intervention 1.725 < 0.001 1.417 2.101
No CVD history 1.203 0.071 0.984 1.470
Numerate 0.937 0.562 0.753 1.167
Reference category  for dependent variable is: Accepted participation
95% Confidence Interval: Odds-ratio
Reference categories for independent variables are: named disease, life-
style intervention, CVD history, innumerate
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with the disease and survey perspective were important. Lacking a continuous
income variable and needing to guarantee sufficient numbers of respondents at
each income level, we created three income categories “below median” (< 600,000
kroner), “median” (600,000-799,000 kroner), and “above median” (>799,999 kroner).
The odds of refusing to pay 150 kroner per month for the cancer prevention program
were 1.6 (p = .007, CI: 1.1 – 2.2) times greater than the odds of being willing to pay
for the lowest income group relative to the highest, 1.6 (p < .001, CI: 1.3 – 2.1) times
higher for those without personal experience with cancer, and 1.4 (p = .014, CI: 1.1 –
1.8) times greater when the individual was considering paying to participate in the
program (individual perspective) rather than paying higher taxes for societal
provision. The odds ratio for the median income group relative to the highest group
was also greater than one, but not significant.
Table 12. Multinomial logistic regression results. Dependent variable:
Willingness to pay 150 NOK/month for Cancer prevention treatment
The final regression explains the choice of preferred prevention program with
the response “both programs are equally valuable” serving as the reference
category. Cases in which individuals chose “don’t know” were omitted from the
regression. The odds of selecting CVD prevention were 1.6 (p = .008, CI: 1.1 – 2.3)
Odds-ratio Sig. Lower bound Upper bound
Unwilling to pay
Below median Y 1.568 0.007 1.130 2.174
Median Y 1.270 0.194 0.886 1.820
No Cancer history 1.629 < 0.001 1.254 2.115
Individual Perspective 1.385 0.140 1.069 1.795
Uncertain
Below median Y 1.763 0.001 1.258 2.469
Median Y 1.493 0.033 1.034 2.156
No Cancer history 1.466 0.005 1.125 1.909
Individual Perspective 1.384 0.015 1.066 1.796
Reference category  for dependent variable is: Willing to pay
95% Confidence Interval: Odds-ratio
Reference categories for independent variables are: above median income, 
cancer history, societal perspective
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times greater than the odds of selecting “both programs are equally valuable” when
the respondent had personal experience with CVD, 1.6 (p = .004, CI: 1.2 – 2.2) times
greater when the disease was “unnamed”, and 0.61 (p = .003, CI: 0.44 - 0.84) times
less when the respondent had personal experience with cancer. The odds of
selecting cancer prevention were 1.5 (p = .008, CI: 1.1 – 2.1) times greater than
saying the programs were equally valuable when a life-style intervention was
offered rather than a pharmaceutical intervention, 0.68 (p = .014, CI: 0.49 – 0.92) times
lower when the disease was “unnamed”, and 0.60 (p = .001, CI: 0.45 – 0.82) times
lower when the respondent had personal experience with CVD. Personal history
with cancer increased the odds ratio but was not significant at the 95% level (p =
.082).
Table 13. Multinomial logistic regression results. Dependent variable: Choice
between prevention programs
Odds-ratio Sig. Lower bound Upper bound
Prefer CVD program
CVD History 1.617 0.008 1.134 2.307
Cancer History 0.609 0.003 0.440 0.842
Unnamed disease 1.611 0.004 1.165 2.226
Life-style intervention 1.158 0.382 0.833 1.610
Prefer Cancer program
CVD history 0.603 0.001 0.446 0.815
Cancer history 1.319 0.082 0.966 1.802
Unnamed disease 0.673 0.014 0.490 0.924
Life-style intervention 1.528 0.008 1.115 2.093
Reference category  for dependent variable is: Both interventions are equally valuable
95% Confidence Interval: Odds-ratio
Reference categories for independent variables are: no CVD history, no 
cancer history, named disease, drug intervention
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4. Discussion and conclusion
Our primary goal in conducting this study was to determine whether information
about increases in life expectancy and changes in the distribution of causes of
death resulting from CDV and cancer prevention programs would influence
willingness to accept preventative treatment against these diseases. We
hypothesized that if individuals have a preference for an “easy” death, they would
be less likely to accept preventative treatment for CVD vs. cancer. Our results
provided little evidence that this is the case. Respondents accepted the offers of
prevention programs against CVD and cancer at similar rates of approximately 61%.
When asked to choose between the two programs, a majority indicated that they
thought the programs were of equal value, and although slightly more of the
remainder preferred cancer prevention, the difference was not statistically
significant. Neither was there a strongly significant difference in the responses of
individuals answering the “short” survey version, in which there was no mention of
changes in the distribution of causes of death, compared to the otherwise identical
“named, individual, pharmaceutical” survey version.
We did find evidence that individuals are sensitive to the way in which questions
are framed. Respondents were more likely to accept preventative treatment that
involved life-style changes rather than pharmaceutical intervention (Odds ratio:
CVD = 2.7, Cancer = 2.4). They were also more likely to accept treatment when the
disease was named in addition to being described (Odds ratio: CVD = 2.2, Cancer =
2.6). This result is consistent with more thorough studies of the affects of naming
(Sackett and Torrance, 1978; Llewelyn-Thomas et al., 1984) and with the theory of
affect heuristics, which suggests that strong emotional response to a word can alter
judgment (Finucane, 2000). Cancer, in particular, is a term that often carries strongly
negative associations that can be far worse than the reality of the disease (Sontag,
1990). Whether surveys involved an individual or societal perspective had little
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effect on responses, although we found slightly more willingness to pay for cancer
prevention when the question was framed a societal rather than individual
perspective.
While a large majority of respondents were willing to participate in both CVD and
cancer prevention programs, relatively few were willing to pay 150 kroner per month,
which reflects a low estimate of the cost of the CVD pharmaceutical intervention, to
do so. For CVD prevention, 42% of those agreeing to participate (26% of all survey
respondents) were willing to pay, while for the cancer prevention program 46% of
those accepting treatment (28% of all respondents) were willing to pay. It is
interesting to note that the minimum value of an extra life-year implied by these
figures is quite low. For CVD treatment, given an average six-month extension in life
expectancy and assuming that individuals would participate in the program for an
average of 30 years, the implied undiscounted value of an extra life-year is 108,000
NOK (approximately $21,600 at $1=5.12 NOK). For cancer treatment, which yields an
average four-month increase in life expectancy with an average of 20 years of
participation, the implied undiscounted value of an extra life-year is also 108,000
NOK. If the stream of payments and benefits are discounted at a rate of 4%, the
value of an extra life-year is 64,735 NOK (approximately $12,950) under the CVD
prevention program and 76,250 NOK (approximately $15,250).
Our study has several limitations that reflect our attempt to design a survey that
focused attention on differences in changes in the distribution of causes of death
resulting from the two prevention programs without overburdening respondents
with a variety of other information. The need to provide balance in the cognitive
demands of the survey is supported by the fact that, even with simplifications, in
some instances survey answers varied according to whether respondents were
“numerate” or not. Descriptions of the diseases were therefore quite brief and
generic, particularly for cancer. While it is not unreasonable to describe a general
pattern of symptoms, disease progression and life expectancy for CVD, the same is
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likely not true for cancer, where experiences vary widely depending on which type
of cancer one considers. Similarly, the prevention programs presented were identical
across diseases, with the pharmaceutical intervention described as requiring daily
medication and extra annual doctor visits, and the life-style intervention described
as requiring changes in diet and significant increases in exercise. It is possible, that,
confronted with the difficult task of assessing the differences in life expectancy and
varying patterns of distributions of causes of death, respondents focused instead
on the similarities between the prevention programs.
Another simplification in our survey was in the choice of method used to describe
gains in life expectancy resulting from prevention programs. We presented the
information as average number of life-years gained. Although such information is
accurate, it provides no information about the expected distribution of gains across
a population. In the case of CVD, for example, a prevention program yielding an
average increased life expectancy of six months would only be expected to benefit
the one-third of the population at risk for CVD, implying an eighteen-month gain in
life expectancy for this group and no benefit for the remaining two-thirds. Gyrd-
Hansen and Kristiansen (2007) found that expected utility from gains in life
expectancy is significantly decreased if the gain is less than six months and
significantly increased if the probability of gains exceeds 0.083. If this is the case,
providing information about the distribution of life expectancy gains might actually
have increased willingness to participate in prevention programs.
A final simplification in our study is that it did not include any mention of
dementia—a chronic disease that individuals are often quite anxious to avoid.
Initially, we intended to include dementia in our analysis of the distribution of
causes of death and provide information about the increased numbers of people
who would die of dementia as a result of extending life through prevention programs
against CVD or cancer. This was not possible, however, because dementia is rarely
reported as a primary cause of death. We also considered calculating the additional
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number of years that individuals were likely to spend in a demented state given
current estimates of the age-specific prevalence of dementia (ranging from 12.2% for
ages 80-84 to 32.5% for ages 95+ [Knapp, Prince, et. al. (2007)]), but decided that
respondents might be unable to easily incorporate this additional information when
deciding whether to support the intervention programs. To the extent that
individuals have a preference for not living in a demented state, there might have
been less support for the CVD prevention program.
In retrospect, we note that we may have forgone the opportunity to obtain better
information about preferences regarding the potential trade-off between more life-
years and a less preferred manner of death by allowing respondents who expressed
willingness to support both CVD and cancer prevention to answer “equally
valuable” when asked to chose between the two. Only one-third of respondents
selected one of the programs, with slightly more preferring cancer prevention.
Greater extension of life expectancy was a popular explanation for those who
preferred the CVD program, while believing that it was worse to die of cancer than
CVD was mentioned frequently among those who chose cancer prevention. It would
have been instructive to have had the opinions of the other two-thirds of
respondents, had they been forced to make a choice.
Our study has examined the influence that information about changes in life
expectancy and the distribution of causes of death has on preferences for CVD and
cancer prevention programs. While our results provided little support for our
hypothesis that such information would reduce demand for CVD prevention, they
did confirm previous findings that the framing of an issue plays an important role in
individual responses. Continued investigation into the best ways of presenting
cognitively challenging information is needed in order to further explore preferences
over the manner of death. If society continues to actively promote CVD prevention,
our study provides evidence that focusing on life-style changes may be most
productive in terms of individuals’ willingness to participate.
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Appendix 1. Survey – NIP version
In Norway, as in most Western countries, life expectancy has increased over the last 100
years. In earlier times, people died at younger ages of infectious diseases such as pneumonia
and tuberculosis. Now, most people live longer lives and die of chronic diseases that develop
over time and which usually are diagnosed after the age of 50. Prevention programs exist that
may postpone the development of a particular chronic disease. Such measures will allow a
slightly longer life, but may ultimately lead to death from another disease. This survey is
being undertaken to gain a better understanding of attitudes about prevention of two chronic
health conditions that many people face in later life. Please read the following descriptions
and respond as carefully as possible to the questions.
Cardiovascular disease
Individuals with cardiovascular disease may experience shortness-of-breath and mild to
severe chest pains in connection with physical activity. Approximately half of patients die
suddenly. The large majority of deaths from cardiovascular disease (almost 9 of 10) occur
after the age of 70.
Cancer
Individuals with cancer may experience loss of appetite, significant unintended weight loss,
fatigue, nausea, and pain. Approximately half of patients are cured, but the others die after 2-3
years with increasingly severe symptoms, including increasing pain. Most deaths (6 in 10)
from cancer occur after the age of 70.
Currently in Norway, out of every 1000 individuals approximately:
342 will die of cardiovascular disease
236 will die of cancer
422 will die of other causes.
Here is a graph showing that information.
Current deaths from various causes per 1000 individuals
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Suppose the health authorities are considering implementing a new disease prevention
program against cardiovascular disease. The program would require that individuals take
daily medication and make annual visits to the doctor for the rest of their lives. This
prevention program extends life by an average of approximately six months and may have
minor side effects. As a result of this program, out of 1000 individuals, 71 fewer people will
die of cardiovascular disease, but 15 more people will die of cancer, and 56 more people will
die of other causes.
Here is a graph comparing the number of deaths from various causes without a prevention
program (the current situation) and with the prevention program against cardiovascular
disease. The blue bars show the current situation. The red bars show the number of deaths if
the program were implemented.
Deaths from various causes per 1000 individuals: 
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1. Would you participate in the prevention program if offered the opportunity free of charge?
Yes (go to question #2)
No (go to question #3)
Uncertain (go to question #3)
2. Would you be willing to pay NOK 150 per month to participate in this prevention
program?
Yes
No
Uncertain
3. Why were you not willing to participate in the prevention program against cardiovascular
disease? (select as many as applicable)
I don’t think the prevention program is of sufficient value
I don’t like to take medications
I don’t want to experience side effects
I do not want to increase my life by 6 months in my old age
I would rather not increase the number of deaths from cancer
I would rather not increase the number of deaths from other causes
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Suppose instead that there is a general, lifelong prevention program against cancer. This
prevention program requires that individuals take daily medication and make annual visits to
the doctor for the rest of their lives. The prevention program would extend life by an average
of approximately 4 months and may have minor side effects. As a result of this prevention
program, 62 fewer people will die of cancer, but 28 more people will die of cardiovascular
disease, and 34 more will die of other causes.
Here is a graph comparing the number of deaths from various causes without a prevention
program (the current situation) and with the prevention program against cancer. The blue bars
show the current situation. The green bars show the number of deaths if the program were
implemented.
Deaths from various causes per 1000 individuals:
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4. Would you participate in the prevention program if offered the opportunity free of charge?
Yes [If yes: go to #5]
No [If no/uncertain: Go to question #6]
Uncertain
5. Would you be willing to pay NOK 150 per month in additional taxes to participate in this
prevention program?
Yes
No
Uncertain
[If 1 & 4 both are yes: go to #7, otherwise go to #9]
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6. Why were you not willing to participate in the prevention program against cancer? 
I don’t think the prevention program is of sufficient value
I don’t like to take medication
I don’t want to experience side effects
I don’t want to extend my life by four months in my old age
I would rather not increase the number of cardiovascular deaths
I would rather not increase the number of other deaths
Here is a graph showing both the current number of deaths from various causes and the
different numbers of deaths from various causes that would occur under each of the two
preventions programs. The blue bars show the current situation, the red bars show the
situation with prevention program against cardiovascular disease, and the green bars show the
situation with the prevention program against cancer.
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7. Suppose you had to choose between the prevention program against cardiovascular disease
and the prevention program against cancer, in which prevention program would you
participate? You can imagine that they have identical costs.
Prevention program against cardiovascular disease
Prevention program against cancer
They are equally valuable
Uncertain
8. [a. IF ANSWER TO #7 = cardiovascular disease] Why do you prefer the prevention
program against cardiovascular disease to the cancer prevention program? (check as many as
applicable)
There are more cases of cardiovascular disease than cancer
The cardiovascular disease prevention offers a greater gain in life expectancy
It would be worse to die from cardiovascular disease than from cancer
I have a family history of cardiovascular disease
I don’t believe that I will get cancer
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[b. IF ANSWER TO #7 = cancer] Why do you prefer the prevention program against
cancer to the cardiovascular prevention program? (check as many as applicable)
Cancer is a more serious disease than cardiovascular disease
It would be worse to die from cancer than cardiovascular disease
I have a family history of cancer
I don’t believe that I will get cardiovascular disease
9. Have you or any close relative (parent, child, sibling, spouse) been diagnosed with or
treated for cardiovascular disease (heart disease)?
Yes
No
Uncertain
10. Have you or any close relative (parent, child, sibling, spouse) been diagnosed with or
treated for any form of cancer?
Yes
No
Uncertain
11. Imagine that you toss a krone in the air. How many times on average do you think it will
land on “krone” if the coin is tossed 1000 times? ____ times out of 1000
12. If the probability that you get a disease is 10%, how many people can expect to get the
disease of 100?  _______ people out of 100
13. Imagine that you are buying a sweater that is reduced by 25% from the original price of
400 kroner. How much do you have to pay for the sweater
100 kroner
250 kroner
300 kroner
400 kroner
500 kroner
Thank you for your participation!
